# Effect of Symbicort ® on GR in Sputum in COPD

> **NCT01787097** · PHASE4 · COMPLETED · sponsor: **Imperial College London** · enrollment: 31 (actual)

## Conditions studied

- Chronic Obstructive Lung Disease

## Interventions

- **DRUG:** Symbicort® total dose 400ug/12ug
- **DRUG:** Symbicort® total dose 800ug/24ug
- **DRUG:** Formoterol 24ug
- **DRUG:** BUD total dose 800ug

## Key facts

- **NCT ID:** NCT01787097
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-12
- **Final completion:** 2015-04
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01787097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01787097, "Effect of Symbicort ® on GR in Sputum in COPD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01787097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*